MRK
Market read
No new filing conclusion is available. 14 of 24 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 32 directly disclosed connections are confirming.
Invalidation: The live read weakens if participation falls to 8 of 24 members or fewer.
Research brief
No new filing conclusion is available. 14 of 24 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 32 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“The higher use of cash in investing activities was primarily due to the acquisition of Cidara and no proceeds from sales of securities and other investments, partially offset by lower capital expenditures (driven in part by the acquisition of a facility from…”10-Q · May 4, 2026 ↗
“The sales declines were also attributable to lower demand in China and ongoing generic competition in most other international markets.”10-Q · Aug 7, 2026 ↗
“Selling, General and Administrative Selling, general and administrative (SG&A) expenses increased 10% and 8% in the second quarter and first six months of 2026, respectively, primarily due to higher administrative costs (including investments in IT), higher p…”10-Q · Aug 7, 2026 ↗
“The gross margin decline in both periods was primarily due to higher amortization of intangible assets, higher inventory write-downs (primarily vaccines), increased restructuring costs, and the recognition of fair value step-up of inventories related to the O…”10-Q · Aug 7, 2026 ↗
Valuation discipline
Price/sales 5.5× · EV/sales 6.0×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 1 Oct, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for MRK. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
Jodie has not yet found a suitable current-versus-prior filing comparison for MRK. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
“This addresses a significant supply challenge: TICE BCG (Merck) has been the sole supplier of BCG product in the U.S.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 34 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
MRK is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
No durable theme membership has been observed for this name yet.